Page 2,659«..1020..2,6582,6592,6602,661..2,6702,680..»

This Stem Cell Breakthrough Helped Two Paralyzed People Feel Again

Posted: September 5, 2012 at 1:10 am

New hope was raised yesterday for people left paralyzed by injury, after doctors said they had succeeded in using stem cells to restore feeling in two patients.

In a world first, doctors at Zurich University said two out of three men who had agreed to take part in an early trial, had regained some sensation below the level of their injuries.

It is the first time anyone has reported a positive outcome from stem cell therapy for severe spinal cord injury - and holds out the possibility of greater things in years to come.

The ultimate aim is to help those paralysed by injury to walk again.

Stem cells are special cells that can turn themselves into almost any kind of cell in the body. Those from human embryos have that absolute ability, while 'adult' stem cells have already specialized to a degree. For instance, neural stem cells can special ise into different type of nerve cells, but not something else like muscle or blood cells.

The trial worked on the theory that injected adult stem cells would transform themselves into spinal cord nerves, reconnecting brain and lower body.

Professor Armin Curt, leading the study, described the result as fundamental.

He said: To find something that can repair the spinal cord is a huge breakthrough. If we can show that something has changed for the better [as a result of stem cell therapy] thats fundamental.

He presented the findings at the annual conference of the International Spinal Cord Society in London on Monday.

Prof Curt was working in partnership with StemCells Inc., a Californian company which also has a base in Cambridge.

View original post here:
This Stem Cell Breakthrough Helped Two Paralyzed People Feel Again

Posted in Stem Cell Videos | Comments Off on This Stem Cell Breakthrough Helped Two Paralyzed People Feel Again

Stem cells help paraplegics regain feeling

Posted: September 5, 2012 at 1:10 am

Professor Armin Curt, leading the study, described the result as fundamental.

He said: To find something that can repair the spinal cord is a huge breakthrough. If we can show that something has changed for the better [as a result of stem cell therapy] thats fundamental.

He presented the findings at the annual conference of the International Spinal Cord Society in London on Monday.

Prof Curt was working in partnership with StemCells Inc., a Californian company which also has a base in Cambridge.

Dr Stephen Huhn, from the firm, said: We think these stem cells are one of the first tools we have for actually repairing the central nervous system.

"To see this kind of change in patients who truly have the worst-of-the-worst type of injury to the spinal cord is very exciting."

The three patients, who all had complete spinal injury where they could feel nothing below the break, were each given a dose of 20 million adult neural stem cells about six months ago.

This was primarily a safety trial, and Prof Curt said monitoring had shown a very good safety profile.

But detailed questioning and objective tests also showed signals were passing up the injured spine to the brain, when they had not before.

One of the patients, Knut lstad, a 46-year-old Norwegian financial consultant, said: Ive noticed changes. When somebody touches my stomach, I can feel something. I cant be specific, but I can sense it.

Read more:
Stem cells help paraplegics regain feeling

Posted in Stem Cell Videos | Comments Off on Stem cells help paraplegics regain feeling

'Missing link' ties blood stem cells, immune system

Posted: September 5, 2012 at 1:10 am

LOS ANGELES UCLA researchers have discovered a type of cell that is the "missing link" between bone marrow stem cells and all the cells of the human immune system, a finding that will lead to a greater understanding of how a healthy immune system is produced and how disease can lead to poor immune function.

The research was done using human bone marrow, which contains all the stem cells that produce blood during post-natal life.

"We felt it was especially important to do these studies using human bone marrow, as most research into the development of the immune system has used mouse bone marrow," said the study's senior author, Dr. Gay Crooks, co-director of UCLA's Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research and a co-director of the cancer and stem-cell biology program at UCLA's Jonsson Comprehensive Cancer Center. "The few studies with human tissue have mostly used umbilical cord blood, which does not reflect the immune system of post-natal life."

The research team was "intrigued to find this particular bone marrow cell, because it opens up a lot of new possibilities in terms of understanding how human immunity is produced from stem cells throughout life," said Crooks, a professor of pathology and pediatrics.

Understanding the process of normal blood formation in human adults is a crucial step in shedding light on what goes wrong during the process that results in leukemias, cancers of the blood.

The findings appeared Sept. 2 in the early online edition of the journal Nature Immunology.

Before this study, researchers had a fairly good idea of how to find and study the blood stem cells of the bone marrow. The stem cells live forever, reproduce themselves and give rise to all the cells of the blood. In the process, the stem cells divide and produce cells in intermediate stages of development called progenitors, which make various blood lineages, like red blood cells or platelets.

Crooks was most interested in the creation of the progenitors that form the entire immune system, which consists of many different cells called lymphocytes, each with a specialized function to fight infection.

"Like the stem cells, the progenitor cells are also very rare, so before we can study them, we needed to find the needle in the haystack," said Lisa Kohn, a member of the UCLA Medical Scientist Training Program and first author of the study.

Previous work had found a fairly mature type of lymphocyte progenitor with a limited ability to differentiate, but the new work describes a more primitive type of progenitor primed to produce the entire immune system, Kohn said.

Read more:
'Missing link' ties blood stem cells, immune system

Posted in Stem Cell Videos | Comments Off on 'Missing link' ties blood stem cells, immune system

Wellington clinic uses stem cells to help heal horses

Posted: September 5, 2012 at 1:10 am

The 1,300-pound patient trembled slightly as an 8-inch needle, carefully placed on the upper rump area, sucked about two ounces of fat tissue from his sleek body.

Its like grating cheese, said a winded Robert Brusie, the staff surgeon at Palm Beach Equine Clinic in Wellington who is performing the medical procedure on a 12-year-old show jumper horse. Racehorses have a lot less body fat, like Olympic swimmers or runners.

Liposuctionfor horses?

Sort of. But its more like regenerative medicine thats helping save careers and even lives.

For the past nine months, to help show horses with slow-healing ligament or tendon injuries, Palm Beach Equine Clinic has been extracting stem cells from fat tissue and injecting those cells back into the horses to repair the injured areas.

Stem cells are simple cells in the body that can develop into various kinds of cells, including blood, skin or intestinal tissues. Stem-cell therapy has had success in treating soft-tissue injuries and arthritis and other joint diseases in horses, degenerative diseases in dogs and such internal medicine problems as kidney disease in cats.

Horses, like the 12-year-old that underwent the 20-minute procedure Tuesday morning, are treated standing up and dont require general anesthesia.

Theyre big animals and getting up and down can be tough for them, said Richard Wheeler, a veterinarian at Palm Beach Equine Clinic. The procedure is not very invasive.

Wheeler said the clinic has performed the procedure on about 20 horses. Before the boom in stem-cell research, veterinarians collected stem cells from the horses bone marrow. It could take a horse a year or several years to recover from an injury, Wheeler said.

Now some are recovering in three months, he added. But since the procedure is still new, Wheeler remains cautiously optimistic.

Read more:
Wellington clinic uses stem cells to help heal horses

Posted in Stem Cell Videos | Comments Off on Wellington clinic uses stem cells to help heal horses

Protein binding sites found in 1,000s of human genes

Posted: September 5, 2012 at 1:10 am

SAN DIEGO A study led by researchers at the UC San Diego Stem Cell Research program and funded by the California Institute for Regenerative Medicine (CIRM) looks at an important RNA binding protein called LIN28, which is implicated in pluripotency and reprogramming as well as in cancer and other diseases. According to the researchers, their study published in Thursday's (Sept. 6) online issue of Molecular Cell will change how scientists view this protein and its impact on human disease.

Studying embryonic stem cells and somatic cells stably expressing LIN28, the researchers defined discrete binding sites of LIN28 in 25 percent of human transcripts. In addition, splicing-sensitive microarrays demonstrated that LIN28 expression causes widespread downstream alternative splicing changes variations in gene products that can result in cancer or other diseases.

"Surprisingly, we discovered that LIN28 not only binds to the non-coding microRNAs, but can also bind directly to thousands of messenger RNAs," said first author Melissa Wilbert, a doctoral student in the UC San Diego Biomedical Sciences graduate program.

Messenger RNA or mRNA, are RNA molecules that encode a chemical "blueprint" for the synthesis of a protein. MicroRNAs (miRNAs) are short snippets of RNA that are crucial regulators of cell growth, differentiation, and death. While they don't encode for proteins, miRNAs are important for regulating protein production in the cell by repressing or "turning off" genes.

"The LIN28 protein is linked to growth and development and is important very early in human development," said principal investigator Gene Yeo, Ph.D., MBA, of the Department of Cellular and Molecular Medicine, the Stem Cell Research Program and the Institute for Genomic Medicine at UC San Diego. "It is usually turned off in adult tissue, but can be reactivated, for instance, in certain cancers or metabolic disorders, such as obesity."

Using genome-wide biochemical methods to look at the set of all RNA molecules across the transcriptome, the researchers found that LIN28 recognizes and binds to a known hairpin-like structure found on the let-7 family of miRNA, but surprisingly, this same structure is also found on mRNAs, allowing LIN28 to directly regulate thousands of targets.

"One of these targets actually encodes for the LIN28 protein itself. In other words, LIN28 helps to make more of itself," said Yeo. This process, known as autoregulation, helps to maintain a so-called "steady-state" system in which a protein positively regulates its own production by binding to a regulatory element of the mRNA for the gene coding it.

"Since these mRNA targets include those known to be involved in gene splicing, we also implicate LIN28 in the regulation of alternative splicing," said Wilbert, adding that abnormal variations in splicing are often implicated in cancer and other disorders.

In the splicing process, fragments that do not typically code for protein, called introns, are removed from gene transcripts, and the remaining sequences, called exons, are reconnected. The splicing factor proteins themselves, as well as the location where these proteins bind, dictate which pieces of the RNA are included or excluded in the final gene transcript - in much the same way that removing and inserting scenes, or splicing, can alter the plot of a movie.

The discovery of thousands of precise binding sites for LIN28 within human genes offers a novel look at the role this protein plays in development and disease processes. For example, scientists had looked at targeting a particular miRNA called let-7 to halt cancer growth. "But we now see that LIN28 can, in essence, bypass let-7 and find many, many other binding sites perhaps with the same adverse effect of uncontrolled cell overgrowth," said Yeo. "This suggests that LIN28 itself should be the therapeutic target for diseases, rather than let-7 or other miRNAs."

See the article here:
Protein binding sites found in 1,000s of human genes

Posted in Stem Cell Research | Comments Off on Protein binding sites found in 1,000s of human genes

Binding sites for LIN28 protein found in thousands of human genes

Posted: September 5, 2012 at 1:10 am

Public release date: 4-Sep-2012 [ | E-mail | Share ]

Contact: Debra Kain ddkain@ucsd.edu 619-543-6163 University of California - San Diego

A study led by researchers at the UC San Diego Stem Cell Research program and funded by the California Institute for Regenerative Medicine (CIRM) looks at an important RNA binding protein called LIN28, which is implicated in pluripotency and reprogramming as well as in cancer and other diseases. According to the researchers, their study published in the September 6 online issue of Molecular Cell will change how scientists view this protein and its impact on human disease.

Studying embryonic stem cells and somatic cells stably expressing LIN28, the researchers defined discrete binding sites of LIN28 in 25 percent of human transcripts. In addition, splicing-sensitive microarrays demonstrated that LIN28 expression causes widespread downstream alternative splicing changes variations in gene products that can result in cancer or other diseases.

"Surprisingly, we discovered that LIN28 not only binds to the non-coding microRNAs, but can also bind directly to thousands of messenger RNAs," said first author Melissa Wilbert, a doctoral student in the UC San Diego Biomedical Sciences graduate program.

Messenger RNA or mRNA, are RNA molecules that encode a chemical "blueprint" for the synthesis of a protein. MicroRNAs (miRNAs) are short snippets of RNA that are crucial regulators of cell growth, differentiation, and death. While they don't encode for proteins, miRNAs are important for regulating protein production in the cell by repressing or "turning off" genes.

"The LIN28 protein is linked to growth and development and is important very early in human development," said principal investigator Gene Yeo, PhD, MBA, of the Department of Cellular and Molecular Medicine, the Stem Cell Research Program and the Institute for Genomic Medicine at UC San Diego. "It is usually turned off in adult tissue, but can be reactivated, for instance, in certain cancers or metabolic disorders, such as obesity."

Using genome-wide biochemical methods to look at the set of all RNA molecules across the transcriptome, the researchers found that LIN28 recognizes and binds to a known hairpin-like structure found on the let-7 family of miRNA, but surprisingly, this same structure is also found on mRNAs, allowing LIN28 to directly regulate thousands of targets.

"One of these targets actually encodes for the LIN28 protein itself. In other words, LIN28 helps to make more of itself," said Yeo. This process, known as autoregulation, helps to maintain a so-called "steady-state" system in which a protein positively regulates its own production by binding to a regulatory element of the mRNA for the gene coding it.

"Since these mRNA targets include those known to be involved in gene splicing, we also implicate LIN28 in the regulation of alternative splicing," said Wilbert, adding that abnormal variations in splicing are often implicated in cancer and other disorders.

Read more here:
Binding sites for LIN28 protein found in thousands of human genes

Posted in Stem Cell Research | Comments Off on Binding sites for LIN28 protein found in thousands of human genes

Cytomedix's AutoloGel System Featured in Continuing Education Program at the Paralyzed Veterans of America Summit 2012

Posted: September 4, 2012 at 11:13 pm

GAITHERSBURG, MD--(Marketwire -09/04/12)- Cytomedix, Inc. (CMXI) (CMXI), a fully integrated regenerative medicine company commercializing and developing innovative platelet and adult stem cell technologies, today announced that the Company's AutoloGel System was highlighted in a continuing education program at the Paralyzed Veterans of America Summit 2012 held August 28 to 30 at the Paris Las Vegas Hotel.

The AutoloGel System is a device for the production of autologous platelet rich plasma ("PRP") gel, and is the only PRP device cleared by the U.S. Food and Drug Administration ("FDA") for use in wound management.

The program, titled, "Platelet Rich Plasma (PRP) Gel for Wounds on Persons with SCI," was delivered by Laurie Rappl, PT, DPT, CWS, Clinical Development Liaison for Cytomedix. Ms. Rappl's discussion addressed the underlying mechanisms of action that allow the Company's physiologically relevant concentration of PRP in the AutoloGel System to accelerate healing in recalcitrant wounds in patients with Spinal Cord Injuries ("SCI"), and highlighted the clinical data demonstrating rapid reduction in wound area and volume, as well as reduction of undermining and sinus tracts/tunnels in non-healing wounds in patients with SCI.

"The physiology of SCI -- such as decreased blood flow, blood pressure and blood supply -- causes impairment at every step of the wound healing process. A physiologically relevant concentration of PRP has been shown to improve healing in even the hardest to treat chronic wounds in SCI patients," noted Ms. Rappl.

"It is especially rewarding for Cytomedix to have a continuing education program highlighting the benefits of the AutoloGel System for the treatment of chronic wounds in SCI patients. Pressure ulcers and other chronic wounds are persistent medical challenges that compromise the health and quality-of-life for these paralyzed patients," stated Martin P. Rosendale, Chief Executive Officer of Cytomedix. "Our clinical data demonstrates how the AutoloGel System's physiologically relevant concentration of PRP can rapidly restart the healing process in complex and chronic wounds, including wounds that were recalcitrant to other treatments."

About The Paralyzed Veterans of America SummitParalyzed Veterans' Summit 2012 + EXPO brings together more than 700 healthcare professionals in SCI and multiple sclerosis (MS) care. Doctors, nurses, occupational therapists, physical therapist, social workers and researchers convene to explore and implement holistic strategies to strengthen the continuum of care for SCI and MS patients.

The Paralyzed Veterans of America Summit serves as an educational venue bringing together professionals representing the full spectrum of SCI and MS healthcare and to support clinicians in their pursuit of maintaining their specialty certification and/or license to practice. The objectives are to enhance multi-specialty care across the lifespan of individuals with SCI and MS; to assess advances in the delivery of healthcare services; to present innovative models of care management; to improve practice skills of clinicians, surgeons, researchers and administrators; to discuss evidence-based medicine; to increase the body of knowledge on spinal cord injury and multiple sclerosis, their medical complications and consequences; to promote educational opportunities; to identify research priorities; and to present data on new developments in assessment and treatment.

About Cytomedix, Inc. Cytomedix, Inc. is a fully integrated regenerative medicine company commercializing and developing innovative platelet and adult stem cell separation products that enhance the body's natural healing processes. The Company's advanced autologous technologies offer clinicians a new treatment paradigm for wound and tissue repair. The Company's patient-derived PRP systems are marketed by Cytomedix in the U.S. and distributed internationally. Our commercial products include the AutoloGel System, cleared by the FDA for wound care and the Angel Whole Blood Separation System. The Company is developing novel regenerative therapies using our proprietary ALDH Bright Cell ("ALDHbr") technology to isolate a unique, biologically active population of a patient's own stem cells. A Phase 2 trial evaluating the use of ALDHbr for the treatment of ischemic stroke is underway. For additional information please visit http://www.cytomedix.com.

Safe Harbor StatementStatements contained in this press release not relating to historical facts are forward-looking statements that are intended to fall within the safe harbor rule for such statements under the Private Securities Litigation Reform Act of 1995. The information contained in the forward-looking statements is inherently uncertain, and Cytomedix' actual results may differ materially due to a number of factors, many of which are beyond Cytomedix' ability to predict or control, including among many others, risks and uncertainties related to the Company's reimbursement related efforts, the Company's ability to capitalize on the benefits of the above-referenced CMS determination, the Company's ability to successfully and favorably conclude the negotiations and related discussions with the above-referenced global pharmaceutical company, the Company's ability to successfully integrate the Aldagen acquisition, to successfully manage contemplated clinical trials, to manage and address the capital needs, human resource, management, compliance and other challenges of a larger, more complex and integrated business enterprise, viability and effectiveness of the Company's sales approach and overall marketing strategies, commercial success or acceptance by the medical community, competitive responses, the Company's ability to raise additional capital and to continue as a going concern, and Cytomedix's ability to execute on its strategy to market the AutoloGel System as contemplated. To the extent that any statements made here are not historical, these statements are essentially forward-looking. The Company uses words and phrases such as "believes", "forecasted," "projects," "is expected," "remain confident," "will" and/or similar expressions to identify forward-looking statements in this press release. Undue reliance should not be placed on forward-looking information. These forward-looking statements are subject to known and unknown risks and uncertainties that could cause actual events to differ from the forward-looking statements. More information about some of these risks and uncertainties may be found in the reports filed with the Securities and Exchange Commission by Cytomedix, Inc. Cytomedix operates in a highly competitive and rapidly changing business and regulatory environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Except as is expressly required by the federal securities laws, Cytomedix undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason. Additional risks that could affect our future operating results are more fully described in our U.S. Securities and Exchange Commission filings, including our Annual Report on Form 10-K for the year ended December 31, 2011 and other subsequent filings. These filings are available at http://www.sec.gov.

Excerpt from:
Cytomedix's AutoloGel System Featured in Continuing Education Program at the Paralyzed Veterans of America Summit 2012

Posted in Regenerative Medicine | Comments Off on Cytomedix's AutoloGel System Featured in Continuing Education Program at the Paralyzed Veterans of America Summit 2012

PropThink: Interim Data In Spinal Cord Injury Driving STEM Higher; PSTI Reacting in Sympathy

Posted: September 4, 2012 at 6:13 pm

This morning, StemCells, Inc. (STEM) released six-month interim results for the first group of patients in its Phase I/II trial, testing the company`s HuCNS-SC (human neural stem cells) treatment candidate in patients with spinal cord injury - previous coverage available here. Shares are trading up nearly 20% in pre-market, and are likely to maintain momentum on the positive news. The interim data showed that thus far, HuCNS-SC treatment led to considerable gains in sensory function in two of three patients vs. their baseline levels of sensation prior to cell transplantation. The company also noted that the treatment continues to exhibit a favorable safety profile. The trial represents the first time that neural stem cells have been transplanted as a potential therapeutic agent for spinal cord injury, and the sensory gains observed have developed in a progressive pattern below the level of injury. Impressively, gains in sensation are not generally expected in spinal cord injury patients, particularly given the severity of injury seen in patients admitted to the Phase I/II study. According to STEM, sensory function of all patients observed thus far was stable before cell transplantation, therefore, the reappearance of sensation is a very positive sign that the treatment is having a beneficial effect. While the third patient did not experience an increase in sensation, that patient`s level of sensation remains stable. PropThink notes that another small-cap stem cell company, PluriStem Therapeutics (PSTI) is also moving in pre-market trading, likely in sympathy with the STEM news.

To see this article at PropThink.com, click here.

About PropThink

PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our focus is on identifying and analyzing technically-complicated companies and equities that are grossly over or under-valued. We offer daily market coverage, weekly feature stories, and a newsletter to investors who subscribe on PropThink.com. To learn more visit us at http://www.propthink.com.

The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: PropThink via Thomson Reuters ONE HUG#1638622

See the article here:
PropThink: Interim Data In Spinal Cord Injury Driving STEM Higher; PSTI Reacting in Sympathy

Posted in Stem Cells | Comments Off on PropThink: Interim Data In Spinal Cord Injury Driving STEM Higher; PSTI Reacting in Sympathy

Research and Markets: Stem Cells – Current Topics in Molecular Cell Biology and Molecular Medicine Series

Posted: September 4, 2012 at 6:13 pm

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/cwsq7k/stem_cells) has announced the addition of John Wiley and Sons Ltd's new book "Stem Cells" to their offering.

This third in the Current Topics in Molecular Cell Biology and Molecular Medicine Series contains a careful selection of new and updated, high-quality articles from the well-known Meyer's Encyclopedia, describing new perspectives in stem cell research. The approximately 40 chapters are divided into four sections: Basic Biology, Stem Cells and Disease, Stem Cell Therapy Approaches, and Laboratory Methods, with the authors chosen from among the leaders in their respective fields.

The two volumes represent an essential guide for students and researchers seeking an overview of the field.

Key Topics Covered:

Introduction to Stem Cells

Basic Biology

Stem Cells, Embryonic

Stem Cells, Adult

Stem Cells in the Adult Brain: Neurogenesis

View original post here:
Research and Markets: Stem Cells - Current Topics in Molecular Cell Biology and Molecular Medicine Series

Posted in Stem Cells | Comments Off on Research and Markets: Stem Cells – Current Topics in Molecular Cell Biology and Molecular Medicine Series

Cleveland researchers find key to stem-cell therapy for MS patients: Discoveries

Posted: September 4, 2012 at 6:13 pm

CLEVELAND, Ohio -- One of the most promising and exciting treatment avenues for multiple sclerosis is the use of a patient's own stem cells to try to stop -- or even repair -- some of the disease's brain tissue damage.

But injecting a patient with a dose of his or her own bone-marrow stem cells was actually a pretty crude method of treating the disease, because no one was quite sure how or why it worked. Last year, doctors at the Cleveland Clinic, University Hospitals Seidman Cancer Center and Case Western Reserve University began trying this for MS patients in a Phase 1 clinical trial after positive results were seen in mice.

Multiple sclerosis is an autoimmune disease in which the immune system attacks the myelin sheaths that surround and protect nerve cells. When myelin is damaged, the nerve cells are exposed and unable to do their job, which is sending signals to the brain and back. This results in the loss of motor skills, coordination and cognitive abilities.

Like many other researchers using stem cells, the local group didn't know exactly how their treatment worked, but they knew that when they gave these human mesenchymal stem cells, or MSCs, to mice with a mouse version of the disease, the mice got better.

Figuring out why the mice improved could help researchers see if the MSC injection will work well in a particular patient before the patient is injected, and possibly augment or improve the treatment as well.

In May, the research group at CWRU, headed up by neurosciences professor Robert Miller, discovered exactly what it is in the stem-cell soup that has a healing effect: a large molecule called hepatocyte growth factor, or HGF. The team published their results in Nature Neuroscience.

Miller's group knew that it could be the stem cells themselves, by coming in physical contact with the myelin damage, that were having a healing effect. Or it could be something the stem cells secreted into the surrounding liquid culture, or media, they were grown in, that was key. HGF is secreted by the stem cells, Miller said.

The team identified the HGF by first injecting only the liquid the stem cells were grown in, but not the stem cells themselves, into the mice they were studying. The mice got better, so the team knew whatever was helping was in the media.

Next, they isolated the small, medium and large molecules from the media and tried each size on the mice. Only the large-molecule treatment had the healing effect, meaning that whatever was helping was somewhere in that mix, Miller said.

"The molecule that jumped out at us was HGF," he said, because it is the right size, is made by MSCs, and in a couple of studies had been shown to be involved in myelin repair.

Go here to see the original:
Cleveland researchers find key to stem-cell therapy for MS patients: Discoveries

Posted in Stem Cells | Comments Off on Cleveland researchers find key to stem-cell therapy for MS patients: Discoveries

Page 2,659«..1020..2,6582,6592,6602,661..2,6702,680..»